PARP inhibitors plus senolytics: a double hit on cancer

A new synthetic lethality approach combines PARP inhibitors with senolytic compounds to boost cancer killing

A new approach to synthetic lethality aims to overcome resistance to PARP inhibitors by pairing them with senolytic agents, marking one of the first moves beyond DNA damage repair combinations.

PARP inhibitors hinder DNA damage repair (DDR) in cancers, and produce a synthetic lethal interaction that enhances cancer killing when

Read the full 493 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers